Trials / Completed
CompletedNCT00536380
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 314 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20 mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria. Subjects with chronic urticaria who are currently taking a second generation antihistamine will be treated with desloratadine (5, 10, or 20 mg) for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5-mg Desloratadine | 5-mg desloratadine tablets, once daily for four weeks. |
| DRUG | 10-mg Desloratadine | 10-mg desloratadine tablets, once daily for four weeks. |
| DRUG | 20-mg Desloratadine | 20-mg desloratadine tablets, once daily for four weeks. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2007-09-27
- Last updated
- 2024-05-23
- Results posted
- 2010-05-03
Source: ClinicalTrials.gov record NCT00536380. Inclusion in this directory is not an endorsement.